JBSS vs SRPT · P/E 13, rev $1.18B vs rev $1.13B
John B Sanfilippo & Son Inc (JBSS) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
John B Sanfilippo & Son Inc (JBSS) is a packaged foods company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported JBSS revenue for 2026-06-25 was $1.18B. Net income was $61.9M. Revenue was up 6.2% from 2025-06-26 to 2026-06-25. JBSS currently screens at market cap $868.4M and trailing P/E 13.0.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
JBSS currently screens at market cap $868.4M and trailing P/E 13.0. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the JBSS and SRPT stock pages for the full models.
Not investment advice.